These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8259343)

  • 21. Antiandrogen withdrawal syndrome with nilutamide.
    Huan SD; Gerridzen RG; Yau JC; Stewart DJ
    Urology; 1997 Apr; 49(4):632-4. PubMed ID: 9111642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
    Gomez JL; Dupont A; Cusan L; Tremblay M; Tremblay M; Labrie F
    Am J Med; 1992 May; 92(5):563-6. PubMed ID: 1580304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Raynaud JP; Husson JM; Fazekas AT
    Horm Res; 1983; 18(1-3):18-27. PubMed ID: 6411578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nilutamide: possible utility as a second-line hormonal agent.
    Desai A; Stadler WM; Vogelzang NJ
    Urology; 2001 Dec; 58(6):1016-20. PubMed ID: 11744479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
    Hucher M; de Gery A; Bertagna C
    Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
    [No Abstract]   [Full Text] [Related]  

  • 28. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Monfette G; Laberge JG; Emond JP; Raynaud JP; Husson JM; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):999-1007. PubMed ID: 6411995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent androgen suppression in the management of prostate cancer.
    Crook JM; Szumacher E; Malone S; Huan S; Segal R
    Urology; 1999 Mar; 53(3):530-4. PubMed ID: 10096379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
    Simard J; Singh SM; Labrie F
    Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiandrogens in combination with LH-RH agonists in prostate cancer.
    Raynaud JP
    Am J Clin Oncol; 1988; 11 Suppl 2():S132-47. PubMed ID: 3071951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary complications of hormone treatment in prostate carcinoma.
    Seigneur J; Trechot PF; Hubert J; Lamy P
    Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of antiandrogens and their mechanisms of action: a case study (anandron).
    Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T
    Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
    Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
    Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
    Beland G
    Urology; 1991; 37(2 Suppl):25-9. PubMed ID: 1992600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.